Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment

Kim,Kyoung   Soo; Choi,Hyun-Mi; Ji,Hye-In; Song,Ran; Yang,Hyung‑In; Lee,Soo-Kon; Yoo,Myung   Chul; Park,Yong-Beom

doi:10.3892/mmr.2013.1764

Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment

Authors:
- Kyoung Soo Kim
- Hyun-Mi Choi
- Hye-In Ji
- Ran Song
- Hyung‑In Yang
- Soo-Kon Lee
- Myung Chul Yoo
- Yong-Beom Park
View Affiliations

Affiliations: East-West Bone and Joint Research Institute, Kyung Hee University Hospital at Gangdong, Kyung Hee University, Gangdong-gu, Seoul, Republic of Korea, Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University Medical School, Gangdong-gu, Seoul, Republic of Korea, Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seodaemoon-gu, Seoul, Republic of Korea
Published online on: October 29, 2013 https://doi.org/10.3892/mmr.2013.1764
Pages: 255-260

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to determine whether disease activity and the type of therapy differentially modulate serum adipokine levels in patients with rheumatoid arthritis (RA), and whether pre-therapy adipokine levels contribute to resistance to treatment. Fasting blood samples from 40 RA patients were obtained at baseline and six months following therapeutic treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of adiponectin, leptin, visfatin and resistin were measured by ELISA. Baseline adipokine levels did not exhibit a statistically significant difference when comparing patients with moderate and high disease activity, based on the disease activity score in 28 joints (DAS28). Of all the adipokines, only adiponectin was significantly increased in patients responding to DMARDs and/or TNF-α blocker therapy, based on the American College of Rheumatology 20% improvement criteria (ACR20) at six months (2,964±1,237 to 3,683±1,511 ng/ml, P<0.01). However, adiponectin levels in non-responders did not significantly increase (3,192±2,090 to 3,222±1,150 ng/ml). By contrast, there were no statistically significant changes in leptin, resistin or visfatin levels in either the responders or non-responders. Serum adipokine (adiponectin, leptin, visfatin, and resistin) levels in RA patients did not significantly change following therapy, with the exception of adiponectin. Adipokine levels may not contribute to therapeutic resistance to DMARDs and/or TNF-α blocking agents.

View Figures

View References

1	Trayhurn P and Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 92:347–355. 2004. View Article : Google Scholar : PubMed/NCBI
2	Wozniak SE, Gee LL, Wachtel MS and Frezza EE: Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 54:1847–1856. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kontny E, Plebanczyk M, Lisowska B, et al: Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Ann Rheum Dis. 71:262–267. 2012. View Article : Google Scholar : PubMed/NCBI
4	Gomez R, Conde J, Scotece M, et al: What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol. 7:528–536. 2011.
5	Neumann E, Frommer KW, Vasile M and Müller-Ladner U: Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum. 63:1159–1169. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ehling A, Schaffler A, Herfarth H, et al: The potential of adiponectin in driving arthritis. J Immunol. 176:4468–4478. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kitahara K, Kusunoki N, Kakiuchi T, Suguro T and Kawai S: Adiponectin stimulates IL-8 production by rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 378:218–223. 2009. View Article : Google Scholar : PubMed/NCBI
8	Stofkova A: Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 43:157–168. 2009.PubMed/NCBI
9	Luk T, Malam Z and Marshall JC: Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol. 83:804–816. 2008. View Article : Google Scholar : PubMed/NCBI
10	Brentano F, Schorr O, Ospelt C, et al: Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 56:2829–2839. 2007. View Article : Google Scholar : PubMed/NCBI
11	Bokarewa M, Nagaev I, Dahlberg L, Smith U and Tarkowski A: Resistin, an adipokine with potent proinflammatory properties. J Immunol. 174:5789–5795. 2005. View Article : Google Scholar : PubMed/NCBI
12	Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315–324. 1988. View Article : Google Scholar : PubMed/NCBI
13	Inoue E, Yamanaka H, Hara M, Tomatsu T and Kamatani N: Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 66:407–409. 2007. View Article : Google Scholar : PubMed/NCBI
14	Fries JF, Spitz P, Kraines RG and Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum. 23:137–145. 1980. View Article : Google Scholar : PubMed/NCBI
15	Felson DT, Anderson JJ, Boers M, et al; American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:727–735. 1995. View Article : Google Scholar : PubMed/NCBI
16	Cansu B, Cansu DU, Kaşifoģlu T, Gülbas Z and Korkmaz C: Disease-modifying antirheumatic drugs increase serum adiponectin levels in patients with rheumatoid arthritis. J Clin Rheumatol. 17:14–17. 2011. View Article : Google Scholar : PubMed/NCBI
17	Lewicki M, Kotyla P and Kucharz E: Etanercept increases adiponectin level in woman with rheumatoid arthritis. Clin Rheumatol. 27:1337–1338. 2008. View Article : Google Scholar : PubMed/NCBI
18	Komai N, Morita Y, Sakuta T, Kuwabara A and Kashihara N: Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol. 17:385–390. 2007. View Article : Google Scholar : PubMed/NCBI
19	Popa C, Netea MG, de Graaf J, et al: Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol. 36:724–730. 2009. View Article : Google Scholar
20	Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, et al: Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol. 28:56–62. 2010.PubMed/NCBI
21	Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, et al: Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol. 26:311–316. 2008.PubMed/NCBI
22	Popa C, Netea MG, Radstake TR, et al: Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis. 64:1195–1198. 2005. View Article : Google Scholar : PubMed/NCBI
23	Presle N, Pottie P, Dumond H, et al: Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage. 14:690–695. 2006. View Article : Google Scholar
24	Senolt L, Pavelka K, Housa D and Haluzik M: Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine. 35:247–252. 2006. View Article : Google Scholar
25	Neumeier M, Weigert J, Schäffler A, et al: Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 79:803–808. 2006. View Article : Google Scholar : PubMed/NCBI